FDA Approves Optiguide Flexible Fiber
Pinnacle Biologics was granted U.S. Food and Drug Administration premarket supplemental approval for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.
Courtesy of Concordia Healthcare Corp.
Used in the treatment of non-small-cell lung and esophageal cancer, the device features a flexible, narrow cylindrical diffuser design that may give physicians greater access to tumors in the right upper lobe of the lung. It also improves maneuverability in other potentially challenging anatomic areas of the bronchus.
In January, the company reached an agreement with the FDA under a special protocol assessment to enroll patients with an advanced form of bile-duct cancer in a pivotal Phase 3 clinical trial, a cancer type for which there is currently no approved therapy.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024